89 related articles for article (PubMed ID: 21590108)
1. The role of growth factors in proliferation and invasion of thyroid cancer.
Hoelting T; Duh Q; Clark O; Herfarth C
Oncol Rep; 1997; 4(3):607-12. PubMed ID: 21590108
[TBL] [Abstract][Full Text] [Related]
2. The regulation of proliferation and invasion in differentiated thyroid cancer by growth factors.
Hoelting T; Duh QY; Clark OH; Herfarth C
Exp Clin Endocrinol Diabetes; 1996; 104 Suppl 4():29-31. PubMed ID: 8980996
[TBL] [Abstract][Full Text] [Related]
3. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor enhances proliferation, migration, and invasion of follicular and papillary thyroid cancer in vitro and in vivo.
Hoelting T; Siperstein AE; Clark OH; Duh QY
J Clin Endocrinol Metab; 1994 Aug; 79(2):401-8. PubMed ID: 8045955
[TBL] [Abstract][Full Text] [Related]
5. Pleiotropic effects of thyroid stimulating hormone in a differentiated thyroid cancer cell line. Studies on proliferation, thyroglobulin secretion, adhesion, migration and invasion.
Zielke A; Hoffmann S; Plaul U; Duh QY; Clark OH; Rothmund M
Exp Clin Endocrinol Diabetes; 1999; 107(6):361-9. PubMed ID: 10543413
[TBL] [Abstract][Full Text] [Related]
6. Follicular thyroid cancer cells: a model of metastatic tumor in vitro (review).
Hoelting T; Goretzki PE; Duh QY
Oncol Rep; 2001; 8(1):3-8. PubMed ID: 11115561
[TBL] [Abstract][Full Text] [Related]
7. Transforming growth factor-beta 1 is a negative regulator for differentiated thyroid cancer: studies of growth, migration, invasion, and adhesion of cultured follicular and papillary thyroid cancer cell lines.
Hölting T; Zielke A; Siperstein AE; Clark OH; Duh QY
J Clin Endocrinol Metab; 1994 Sep; 79(3):806-13. PubMed ID: 8077365
[TBL] [Abstract][Full Text] [Related]
8. Treatment and surveillance of advanced, metastatic iodine-resistant differentiated thyroid cancer.
Ibrahim EY; Busaidy NL
Curr Opin Oncol; 2017 Mar; 29(2):151-158. PubMed ID: 28141684
[TBL] [Abstract][Full Text] [Related]
9. Updates on the Management of Advanced, Metastatic, and Radioiodine Refractory Differentiated Thyroid Cancer.
Tumino D; Frasca F; Newbold K
Front Endocrinol (Lausanne); 2017; 8():312. PubMed ID: 29209273
[TBL] [Abstract][Full Text] [Related]
10. Biphasic effects of thyrotropin on invasion and growth of papillary and follicular thyroid cancer in vitro.
Hoelting T; Tezelman S; Siperstein AE; Duh QY; Clark OH
Thyroid; 1995 Feb; 5(1):35-40. PubMed ID: 7787431
[TBL] [Abstract][Full Text] [Related]
11. The Effect of Thyroid-Stimulating Hormone on Tumor Size in Differentiated Thyroid Carcinoma.
Ozemir IA; Gurbuz B; Bayraktar B; Aslan S; Başkent A; Yalman H; Yigitbasi R; Alimoglu O
Indian J Surg; 2015 Dec; 77(Suppl 3):967-70. PubMed ID: 27011492
[TBL] [Abstract][Full Text] [Related]
12. Serum vascular endothelial growth factor levels are elevated in metastatic differentiated thyroid cancer but not increased by short-term TSH stimulation.
Tuttle RM; Fleisher M; Francis GL; Robbins RJ
J Clin Endocrinol Metab; 2002 Apr; 87(4):1737-42. PubMed ID: 11932308
[TBL] [Abstract][Full Text] [Related]
13. Highly Concordant Key Genetic Alterations in Primary Tumors and Matched Distant Metastases in Differentiated Thyroid Cancer.
Sohn SY; Park WY; Shin HT; Bae JS; Ki CS; Oh YL; Kim SW; Chung JH
Thyroid; 2016 May; 26(5):672-82. PubMed ID: 26971368
[TBL] [Abstract][Full Text] [Related]
14. Bridging hypoxia, inflammation and estrogen receptors in thyroid cancer progression.
Tafani M; De Santis E; Coppola L; Perrone GA; Carnevale I; Russo A; Pucci B; Carpi A; Bizzarri M; Russo MA
Biomed Pharmacother; 2014 Feb; 68(1):1-5. PubMed ID: 24286852
[TBL] [Abstract][Full Text] [Related]
15. Endothelial Cell Proliferation and Vascular Endothelial Growth Factor Expression in Primary Colorectal Cancer and Corresponding Liver Metastases.
Raluca BA; Cimpean AM; Cioca A; Cretu O; Mederle O; Ciolofan A; Gaje P; Raica M
Asian Pac J Cancer Prev; 2015; 16(11):4549-53. PubMed ID: 26107202
[TBL] [Abstract][Full Text] [Related]
16. Encapsulated miR-200c and Nkx2.1 in a nuclear/mitochondria transcriptional regulatory network of non-metastatic and metastatic lung cancer cells.
D'Almeida O; Mothar O; Bondzie EA; Lieumo Y; Tagne L; Gupta S; Volkert T; Levine S; Tagne JB
BMC Cancer; 2019 Feb; 19(1):136. PubMed ID: 30744585
[TBL] [Abstract][Full Text] [Related]
17. Targeting epidermal growth factor receptor 1 signaling in human thyroid-stimulating hormone-independent thyroid carcinoma FRO cells results in a more chemosensitive and less angiogenic phenotype.
Landriscina M; Piscazzi A; Fabiano A; Maddalena F; Costantino E; Farese A; Bufo P; Cignarelli M
Thyroid; 2009 Jun; 19(6):629-37. PubMed ID: 19499990
[TBL] [Abstract][Full Text] [Related]
18. Loss of sorting nexin 5 stabilizes internalized growth factor receptors to promote thyroid cancer progression.
Jitsukawa S; Kamekura R; Kawata K; Ito F; Sato A; Matsumiya H; Nagaya T; Yamashita K; Kubo T; Kikuchi T; Sato N; Hasegawa T; Kiyonari H; Mukumoto Y; Takano KI; Himi T; Ichimiya S
J Pathol; 2017 Nov; 243(3):342-353. PubMed ID: 28771744
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analog octreotide inhibits the growth of differentiated thyroid cancer cells in vitro, but not in vivo.
Hoelting T; Duh QY; Clark OH; Herfarth C
J Clin Endocrinol Metab; 1996 Jul; 81(7):2638-41. PubMed ID: 8675590
[TBL] [Abstract][Full Text] [Related]
20. Increased Global DNA Hypomethylation in Distant Metastatic and Dedifferentiated Thyroid Cancer.
Klein Hesselink EN; Zafon C; Villalmanzo N; Iglesias C; van Hemel BM; Klein Hesselink MS; Montero-Conde C; Buj R; Mauricio D; Peinado MA; Puig-Domingo M; Riesco-Eizaguirre G; Reverter JL; Robledo M; Links TP; Jordà M
J Clin Endocrinol Metab; 2018 Feb; 103(2):397-406. PubMed ID: 29165662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
